Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People's Republic of China. The company's therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates comprising STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; STP369 to treat head and neck cancer; and STP707 and STP355 to treat solid tumors. The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G, STP145G, and STP146G for the treatment of complement diseases. In addition, it is developing STP247G to treat complement diseases; STP152G to treat amyloidosis; STP705 for fat reduction; STP237G and STP251G for the treatment of hypertension in combination with familial hypertriglyceridemia; and STP136G to treat hypertension. The company was incorporated in 2007 and is headquartered in Germantown, Maryland.
Frequently asked questions
What sector does Sirnaomics Ltd (2257) operate in?
Sirnaomics Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Sirnaomics Ltd (2257) current stock price?
As of the latest data, Sirnaomics Ltd stock price is HK$3.71, with a previous close of HK$3.68. Sirnaomics Ltd gained HK$0.03 in the last trading session, representing a 0.82% increase.
What is Sirnaomics Ltd (2257) current market capitalization?
Sirnaomics Ltd market cap is approximately 413.05 million.
What is Sirnaomics Ltd (2257) EBITDA?
Sirnaomics Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.51 million.
Does Sirnaomics Ltd (2257) pay dividends?
No. Sirnaomics Ltd does not pay a dividend.
What is Sirnaomics Ltd (2257) beta (volatility) score?
Sirnaomics Ltd has a beta of -0.044, indicating lower volatility than the overall market.
